Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Transcripta Bio raises $24 million in a Series A funding round led by Mayo Clinic and Omnimed to advance AI-powered drug discovery for neurological diseases.

PRIVATEJul 22, 2026•18 days ago

Amount Raised

$24 Million

Round Type

Series A

Palo AltoBiotechnologyHealth CareArtificial IntelligenceTherapeutics

Investors

Blue Yard CapitalJazz Venture PartnersOmnimedMayo Clinic

Description

Transcripta Bio has announced it raised $24 million since its Series A. The funding will be used to advance IND-enabling studies and support clinical preparation for programs targeting Autism Spectrum Disorder and Facioscapulohumeral Muscular Dystrophy. The round included new participation from Mayo Clinic and Omnimed alongside existing investors. This capital aims to enhance their AI-powered drug discovery platform.

Company Information

Company

Transcripta Bio

Location

Palo Alto, California, United States

About

Transcripta Bio is an AI-powered drug discovery company that focuses on developing treatments for neurological and neuromuscular diseases. The company aims to advance its portfolio through IND-enabling studies and prepare for clinical trials, particularly in Autism Spectrum Disorder (ASD) and Facioscapulohumeral Muscular Dystrophy (FSHD).

Related People

Suggested for you

2 contacts

Verified contactsOnno, CEO hidden

Predictive Intelligence

Strategic

ML-powered predictions for Transcripta Bio's next move

Learn about Strategic plan

Funding Insights

Based on industry data

Typical timeline to Series B

Series A companies typically raise their next round in 10-18 months

Monthly burn rate benchmark

47% of Series A startups spend $400k or more per month on operations

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech